Top

Published in:

Open Access 13-11-2024 | Benign Prostatic Hypertrophy | Original Research Article

A Pharmacovigilance Study on Psychotropic Agent-Induced Urinary Retention Using the Japanese Adverse Drug Event Report Database

Authors: Shusuke Uekusa, Keika Mogi, Yuki Ota, Yuki Hanai, Kohei Kitagawa, Takashi Yoshio, Kazuhiro Matsuo

Published in: Drugs - Real World Outcomes | Issue 4/2024

Abstract

Introduction

Psychotropic drugs have been reported to cause urinary retention (UR) via anticholinergic and other mechanisms. However, UR has not received much attention because of its non-fatal symptoms. We investigated the occurrence of UR associated with psychotropic drugs using the Japanese Adverse Drug Event Report (JADER) database.

Methods

Using the JADER database, we calculated reporting odds ratios for UR for 74 psychotropic drugs. Multivariate logistic regression analysis was used to adjust for the effects of sex, underlying disease, and age on UR. Variable selection included forced entry for sex, age, benign prostatic hyperplasia (BPH), depression, and backward-forward stepwise selection for each drug.

Results

A total of 887,704 cases were reported, of which 4653 (0.52%) had UR. In terms of sex, 0.79% (3401/429,372 cases) and 0.43% (1797/415,358 cases) of male and female patients had UR. In terms of age, 0.31% (892/288,676 cases) and 0.68% (3463/506,907 cases) of patients aged < 60 years and 60 years or older had UR. Among the underlying diseases, 8.22% (930/11,316 cases) and 0.43% (3723/876,388 cases) of patients with BPH and without BPH had UR, respectively. Further, 1.99% (337/16,959 cases) and 0.50% (4316/870,745 cases) of patients with depression and without depression had UR, respectively. Overall, 38 psychotropic drugs met the criteria for signal detection. In logistic regression, a total of 783,083 patients of discernible age and sex were included. The selected variables were sex, age, BPH, depression, and 23 drugs, including quetiapine [adjusted reporting odds ratio (ROR) 95% confidence interval (CI): 1.46–2.81], chlorpromazine (adjusted ROR 95%CI: 1.29–3.13), etizolam (adjusted ROR 95%CI: 1.47–3.09), maprotiline (adjusted ROR 95%CI: 1.99–8.34), mirtazapine (adjusted ROR 95%CI: 1.37–2.88), and duloxetine (adjusted ROR 95%CI: 2.15–4.21).

Conclusions

Many psychotropic drugs induce UR, which may be owing to their pharmacological effects. Appropriate monitoring is needed, especially in patients with other risk factors for UR.

Thomas K, Chow K, Kirby RS. Acute urinary retention: a review of the aetiology and management. Prostate Cancer Prostatic Dis. 2004;7:32–7. https://doi.org/10.1038/sj.pcan.4500700.CrossRefPubMed

Verhamme KM, Sturkenboom MC, Stricker BH, Bosch R. Drug-induced urinary retention: incidence, management and prevention. Drug Saf. 2008;31:373–88. https://doi.org/10.2165/00002018-200831050-00002.CrossRefPubMed

Obara K, Chino D, Tanaka Y. The recovery effects of distigmine on guinea pig detrusor underactivity induced by anticholinergic drugs. Ōyō Yakuri Pharmacometr. 2016;91:25–39.

Trinchieri M, Perletti G, Magri V, Stamatiou K, Montanari E, Trinchieri A. Urinary side effects of psychotropic drugs: a systematic review and metanalysis. Neurourol Urodyn. 2021;40:1333–48. https://doi.org/10.1002/nau.24695.CrossRefPubMed

Obara K, Matsuoka Y, Iwata N, Abe Y, Ikegami Y, Shioda N, et al. Inhibitory effects of antipsychotics on the contractile response to acetylcholine in rat urinary bladder smooth muscles. Biol Pharm Bull. 2021;44:1140–50. https://doi.org/10.1248/bpb.b21-00363.CrossRefPubMed

Obara K, Imanaka S, Fukuhara H, Yamaki F, Matsuo K, Yoshio T, et al. Evaluation of the potentiating effects of antidepressants on the contractile response to noradrenaline in guinea pig urethra smooth muscles. Clin Exp Pharmacol Physiol. 2019;46:444–55. https://doi.org/10.1111/1440-1681.13072.CrossRefPubMed

Obara K, Ao L, Ogawa T, Ikarashi T, Yamaki F, Matsuo K, et al. Assessment of inhibitory effects of hypnotics on acetylcholine-induced contractions in isolated rat urinary bladder smooth muscle. Biol Pharm Bull. 2019;42:280–8. https://doi.org/10.1248/bpb.b18-00829.CrossRefPubMed

Uno J, Obara K, Suzuki H, Miyatani S, Chino D, Yoshio T, et al. Inhibitory effects of antidepressants on acetylcholine-induced contractions in isolated guinea pig urinary bladder smooth muscle. Pharmacology. 2017;99:89–98. https://doi.org/10.1159/000452221.CrossRefPubMed

Obara K, Ao L, Shimada T, Horiguchi S, Ikarashi T, Ogawa T, et al. Pharmacological characteristics of anxiolytics on acetylcholine-induced contractions in rat detrusor smooth muscle. Pharmacology. 2020;105:369–76. https://doi.org/10.1159/000503885.CrossRefPubMed

10.

Pharmaceuticals and Medical Devices Agency. [Japanese adverse drug event report database]. Accessed 2021 Dec 1. https://www.pmda.go.jp/safety/info-services/drugs/adr-info/suspected-adr/0004.html (in Japanese)

11.

Meigs JB, Barry MJ, Giovannucci E, Rimm EB, Stampfer MJ, Kawachi I. Incidence rates and risk factors for acute urinary retention: the health professionals followup study. J Urol. 1999;162:376–82. https://doi.org/10.1016/S0022-5347(05)68563-1.CrossRefPubMed

12.

Klarskov P, Andersen JT, Asmussen CF, Brenøe J, Jensen SK, Jensen IL, et al. Acute urinary retention in women: a prospective study of 18 consecutive cases. Scand J Urol Nephrol. 1987;21:29–31. https://doi.org/10.3109/00365598709180286.CrossRefPubMed

13.

Jacobsen SJ, Jacobson DJ, Girman CJ, Roberts RO, Rhodes T, Guess HA, et al. Natural history of prostatism: risk factors for acute urinary retention. J Urol. 1997;158:481–7. https://doi.org/10.1016/s0022-5347(01)64508-7.CrossRefPubMed

14.

Ramsey S, Palmer M. The management of female urinary retention. Int Urol Nephrol. 2006;38:533–5. https://doi.org/10.1007/s11255-005-5790-9.CrossRefPubMed

15.

Verhamme KM, Dieleman JP, van Wijk MA, Bosch JL, Stricker BH, Sturkenboom MC. Low incidence of acute urinary retention in the general male population: the triumph project. Eur Urol. 2005;47:494–8. https://doi.org/10.1016/j.eururo.2004.11.011.CrossRefPubMed

16.

Cathcart P, van der Meulen J, Armitage J, Emberton M. Incidence of primary and recurrent acute urinary retention between 1998 and 2003 in England. J Urol. 2006;176:200–4. https://doi.org/10.1016/S0022-5347(06)00509-X.CrossRefPubMed

17.

Abarbanel J, Marcus EL. Impaired detrusor contractility in community-dwelling elderly presenting with lower urinary tract symptoms. Urology. 2007;69:436–40. https://doi.org/10.1016/j.urology.2006.11.019.CrossRefPubMed

18.

De Ridder D, Ost D, Bruyninckx F. The presence of Fowler’s syndrome predicts successful long-term outcome of sacral nerve stimulation in women with urinary retention. Eur Urol. 2007;51:229–33. https://doi.org/10.1016/j.eururo.2006.06.031. (discussion 233–4).CrossRefPubMed

19.

Hoeritzauer I, Stone J, Fowler C, Elneil-Coker S, Carson A, Panicker J. Fowler’s syndrome of urinary retention: a retrospective study of co-morbidity. Neurourol Urodyn. 2016;35:601–3. https://doi.org/10.1002/nau.22758.CrossRefPubMed

20.

Hwang YJ, Dixon SN, Reiss JP, Wald R, Parikh CR, Gandhi S, et al. Atypical antipsychotic drugs and the risk for acute kidney injury and other adverse outcomes in older adults: a population-based cohort study. Ann Intern Med. 2014;161:242–8. https://doi.org/10.7326/M13-2796.CrossRefPubMed

21.

Ou H, Chang HA, Kao YC, Tzeng NS. Risperidone-induced acute urinary retention in a patient with major depressive disorder with psychotic features: a case report. Am J Ther. 2021;28:e585–7. https://doi.org/10.1097/MJT.0000000000001414.CrossRefPubMed

22.

Cohen R, Wilkins KM, Ostroff R, Tampi RR. Olanzapine and acute urinary retention in two geriatric patients. Am J Geriatr Pharmacother. 2007;5:241–6. https://doi.org/10.1016/j.amjopharm.2007.09.003.CrossRefPubMed

23.

Jiang Y, McCombs JS, Park SH. A retrospective cohort study of acute kidney injury risk associated with antipsychotics. CNS Drugs. 2017;31:319–26. https://doi.org/10.1007/s40263-017-0421-4.CrossRefPubMed

24.

Hsu WY, Chang TG, Chiu NY. Aripiprazole associated urine retention in a male schizophrenia patient. Gen Hosp Psychiatry. 2013;35(680):e11–2. https://doi.org/10.1016/j.genhosppsych.2013.04.008.CrossRef

25.

Kahn B, Boazak M, Ragazino J, Sineath RC, Kapral T. An additive mix? Acute urinary retention in a patient with benign prostatic hyperplasia treated with Suboxone, lurasidone, and trazodone. Focus (Am Psychiatr Publ). 2018;16:292–8. https://doi.org/10.1176/appi.focus.20180007.CrossRefPubMedPubMedCentral

26.

Merrill DC, Markland C. Vesical dysfunction induced by the major tranquilizers. J Urol. 1972;107:769–71. https://doi.org/10.1016/s0022-5347(17)61136-4.CrossRefPubMed

27.

Ulmar G, Schunck H, Kober C. Urinary retention in the course of neuroleptic therapy with haloperidol. Pharmacopsychiatry. 1988;21:208–9. https://doi.org/10.1055/s-2007-1014677.CrossRefPubMed

28.

Xomalis D, Bozikas VP, Garyfallos G, Nikolaidis N, Giouzepas J, Fokas K. Urinary hesitancy and retention caused by ziprasidone. Int Clin Psychopharmacol. 2006;21:71–2. https://doi.org/10.1097/01.yic.0000182117.49887.e7.CrossRefPubMed

29.

Bozikas V, Petrikis P, Karavatos A. Urinary retention caused after fluoxetine-risperidone combination. J Psychopharmacol. 2001;15:142–3. https://doi.org/10.1177/026988110101500201.CrossRefPubMed

30.

Davies MA, Compton-Toth BA, Hufeisen SJ, Meltzer HY, Roth BL. The highly efficacious actions of N-desmethylclozapine at muscarinic receptors are unique and not a common property of either typical or atypical antipsychotic drugs: is M1 agonism a pre-requisite for mimicking clozapine’s actions? Psychopharmacol (Berl). 2005;178:451–60. https://doi.org/10.1007/s00213-004-2017-1.CrossRef

31.

Sur C, Mallorga PJ, Wittmann M, Jacobson MA, Pascarella D, Williams JB, et al. N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl-d-aspartate receptor activity. Proc Natl Acad Sci U S A. 2003;100:13674–9. https://doi.org/10.1073/pnas.1835612100.CrossRefPubMedPubMedCentral

32.

Maany I, Greenfield H, Dhopesh V, Woody G. Urinary retention as a possible complication of long-term diazepam abuse. Am J Psychiatry. 1991;148:685. https://doi.org/10.1176/ajp.148.5.685b.CrossRefPubMed

Title: A Pharmacovigilance Study on Psychotropic Agent-Induced Urinary Retention Using the Japanese Adverse Drug Event Report Database
Authors: Shusuke Uekusa
Keika Mogi
Yuki Ota
Yuki Hanai
Kohei Kitagawa
Takashi Yoshio
Kazuhiro Matsuo
Publication date: 13-11-2024
Publisher: Springer International Publishing
Keywords: Benign Prostatic Hypertrophy
Benign Prostatic Hypertrophy
Maprotiline
Quetiapine
Mirtazapine
Mirtazapine
Duloxetine
Antipsychotics
Antipsychotics
Benzodiazepine
Antidepressant Drugs
Antidepressant Drugs
Published in: Drugs - Real World Outcomes / Issue 4/2024
Print ISSN: 2199-1154
Electronic ISSN: 2198-9788
DOI: https://doi.org/10.1007/s40801-024-00465-8

Evaluating the Effectiveness of Prophylactic Strategies for Hemophilia A Management: A Real-World, Longitudinal Observational Study

Open Access
Hemophilia
Original Research Article

US Clinical Practice Experience with Eculizumab in Myasthenia Gravis: Acute Clinical Events and Healthcare Resource Utilization

Open Access
Eculizumab
Original Research Article

Prescription Patterns of Inducers and Inhibitors of Cytochrome P450 and Their Potential Drug Interactions in the Real World: A Cross-Sectional Study

Open Access
Fluconazole
Original Research Article

Comparison of the Safety of Aspirin Monotherapy and Aspirin and P2Y12 Inhibitor Combination Therapy in Patients Post Coil Embolization During Admission: A Cross-Sectional Study Using a Nationwide Inpatient Database

Open Access
Subarachnoid Hemorrhage
Original Research Article

A Pilot Study on the Collection of Adverse Event Data from the Patient Using an Electronic Platform in a Cancer Clinical Trial Unit

Open Access
Original Research Article

Real-World Evidence of Clinical Outcomes of the Use of the Adalimumab Biosimilar SB5 in Rheumatic and Gastrointestinal Immune-Mediated Inflammatory Diseases: 12-Month Data from the PERFUSE Study

Open Access
Adalimumab
Original Research Article

Podcast | Sexual health in older age

Springer Medicine

A Pharmacovigilance Study on Psychotropic Agent-Induced Urinary Retention Using the Japanese Adverse Drug Event Report Database

Abstract

Introduction

Methods

Results

Conclusions

Other articles of this Issue 4/2024

Evaluating the Effectiveness of Prophylactic Strategies for Hemophilia A Management: A Real-World, Longitudinal Observational Study

US Clinical Practice Experience with Eculizumab in Myasthenia Gravis: Acute Clinical Events and Healthcare Resource Utilization

Prescription Patterns of Inducers and Inhibitors of Cytochrome P450 and Their Potential Drug Interactions in the Real World: A Cross-Sectional Study

Comparison of the Safety of Aspirin Monotherapy and Aspirin and P2Y12 Inhibitor Combination Therapy in Patients Post Coil Embolization During Admission: A Cross-Sectional Study Using a Nationwide Inpatient Database

A Pilot Study on the Collection of Adverse Event Data from the Patient Using an Electronic Platform in a Cancer Clinical Trial Unit

Real-World Evidence of Clinical Outcomes of the Use of the Adalimumab Biosimilar SB5 in Rheumatic and Gastrointestinal Immune-Mediated Inflammatory Diseases: 12-Month Data from the PERFUSE Study

Podcast | Sexual health in older age

Springer Medicine

Abstract

Introduction

Methods

Results

Conclusions

Please log in to get access to this content

Evaluating the Effectiveness of Prophylactic Strategies for Hemophilia A Management: A Real-World, Longitudinal Observational Study

US Clinical Practice Experience with Eculizumab in Myasthenia Gravis: Acute Clinical Events and Healthcare Resource Utilization

Prescription Patterns of Inducers and Inhibitors of Cytochrome P450 and Their Potential Drug Interactions in the Real World: A Cross-Sectional Study

Comparison of the Safety of Aspirin Monotherapy and Aspirin and P2Y12 Inhibitor Combination Therapy in Patients Post Coil Embolization During Admission: A Cross-Sectional Study Using a Nationwide Inpatient Database

A Pilot Study on the Collection of Adverse Event Data from the Patient Using an Electronic Platform in a Cancer Clinical Trial Unit

Real-World Evidence of Clinical Outcomes of the Use of the Adalimumab Biosimilar SB5 in Rheumatic and Gastrointestinal Immune-Mediated Inflammatory Diseases: 12-Month Data from the PERFUSE Study